Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime

Pharmacotherapy

Volumn 34, Issue 7, 2014, Pages 662-669

  Gomes, Diane M ^a   Smotherman, Carmen ^b   Birch, Amy ^a   Dupree, Lori ^a   Della Vecchia, Bethany J ^a   Kraemer, Dale F ^a,b   Jankowski, Christopher A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Center for Health Equity and Quality Research   (United States)

Author keywords

acute kidney injury; cefepime; nephrotoxicity; piperacillin tazobactam; vancomycin

Indexed keywords

CEFEPIME; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; ACUTE KIDNEY INJURY; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84903883207     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1428     Document Type: Article

References (34)

1. MacDougall C, Polk RE,. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008; 3: 203-11.
2. Pakyz AL, MacDougall C, Oinonen M, Polk RE,. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008; 20: 2254-60.
3. Jensen JU, Hein L, Lundgren B, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open 2012; 2: 1-8.
4. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 1: 82-98.
5. Vaidya VS, Ferguson MA, Bonventre JV,. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008; 48: 463-93.
6. Akcay A, Turkmen K, Lee D, Edelstein CL,. Update on the diagnosis and management of acute kidney injury. Int J Nephrol Renovasc Dis 2010; 3: 129-40.
7. Wajida G, Fatica R,. Drug-induced acute kidney injury in the ICU. American College of Chest Physicians 2008; 22. Available from http://69.36.35.38/accp/pccsu/drug-induced-acute-kidney-injury-icu?page=0,3. Accessed August 2, 2012.
8. Gupta A, Biyani M, Khaira A,. Vancomycin nephrotoxicity: myths and facts. Neth J Med 2011; 9: 379-83.
9. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 4: 1330-6.
10. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 4: 507-14.
11. Wong-Beringer A, Joo J, Tse E, Beringer P,. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 2: 95-101.
12. Burgess L, Drew R,. Incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillintazobactam [abstract 123E]. In: Abstracts of the 44th Southeastern Residency Conference. Athens, GA: Southeastern Residency Conference, 2013.
13. Hellwig T, Hammerquist R, Loecker B, Shields J,. Retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure [abstract 301]. Crit Care Med 2011; 12: 79.
14. McCormick HTN, Baggett S, Heierman T, LaFosse J, Gilbert S, Imhof K,. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam. J Health Syst Pharm Res 2011; 1: 1-5.
15. Min E, Box K, Lane J, et al. Acute kidney injury in patients recieving concomitant vancomycin and piperacillin/tazobactam [abstract 714]. Crit Care Med 2011; 39: 200.
16. Moenster RP, Linneman TW, Finnegan PM, Hand S, Thomas Z, McDonald JR,. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin/tazobactam compared to cefepime. Clin Microbiol Infect 2013; Oct 1. [Epub ahead of print] doi: 10.1111/1469-0691.12410.
17. O'Rourke K,. Vancomycin Plus Piperacillin-Tazo May Trigger Acute Kidney Injury. Pharmacy Practice News 39 (June 2012). Available from http://www.pharmacypracticenews.com. Accessed August 2, 2012.
18. Patel R, Choe R, Kisgen J,. Retrospective analysis to determine the incidence of acute kidney injury in patients treated with piperacillin- tazobactam, vancomycin or the combination. In: Program and abstracts of the 2nd Annual Florida Residency Conference. Orlando, FL: Florida Society of Health-System Pharmacists Research and Education Foundation, 2013.
19. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Network Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1-138.
20. SAS Institute Inc. SAS Version 9.3 for Windows, Cary, NC: SAS Institute Inc.; 2008.
21. Parsons LS, ed. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Long Beach, CA, 2001.
22. King DW, Smith MA,. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro 2004; 6: 797-803.
23. Le Moyec L, Racine S, Le Toumelin P, et al. Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Crit Care Med 2002; 6: 1242-5.
24. Nishino Y, Takemura S, Minamiyama Y, et al. Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat. Redox Rep 2002; 5: 317-9.
25. Baldwin DS, Levine BB, McCluskey RT, Gallo GR,. Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med 1968; 23: 1245-52.
26. Liu P, Tepperman BS, Logan AG,. Acute renal failure induced by semi-synthetic penicillins. Can Fam Physician 1981; 27: 507-12.
27. Pratt JA, Stricherz MK, Verghese PS, Burke MJ,. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. Pediatr Blood Cancer 2014; 61: 366-8.
28. Liu TJ, Lam JP,. Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis. Am J Health Syst Pharm 2012; 13: 1109.
29. Sakarcan A, Marcille R, Stallworth J,. Antibiotic-induced recurring interstitial nephritis. Pediatr Nephrol 2002; 1: 50-1.
30. Mannaerts L, Van der Wurff AA, Wolfhagen FH,. Interstitial nephritis attributed to treatment with piperacillin-tazobactam and with ciprofloxacin [in Dutch]. Ned Tijdschr Geneeskd 2006; 14: 804-7.
31. Bajaj P, Prematta MJ, Ghaffari G,. A sixty-five-year-old man with rash, fever, and generalized weakness. Allergy Asthma Proc 2011; 1: e1-3.
32. Pill MW, O'Neill CV, Chapman MM, Singh AK,. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy 1997; 1: 166-9.
33. Appel GB, Neu HC,. The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med 1977; 12: 663-70.
34. Campagna JD, Bond MC, Schabelman E, Hayes BD,. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med 2012; 5: 612-20.